The global market for Semi-Solid Dosage CDMO was estimated at US$33.5 Billion in 2024 and is projected to reach US$60.8 Billion by 2030, growing at a CAGR of 10.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Semi-Solid Dosage CDMO market.
Segments: Administration Route (Topical, Transdermal, Others); Product (Ointments, Creams & Lotions, Pastes, Gels, Others); Service (Contract Development, Contract Manufacturing); End-Use (Pharmaceutical Companies, Biopharmaceutical Companies, Others)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Semi-Solid Dosage CDMO Market - Key Trends & Drivers Summarized
Why Are Semi-Solid Dosage CDMOs Gaining Importance In Pharmaceutical Manufacturing?
Semi-solid dosage contract development and manufacturing organizations (CDMOs) are playing a vital role in the pharmaceutical industry by providing expertise in formulating creams, gels, ointments, and suppositories. As pharmaceutical companies seek to outsource development and production to specialized manufacturers, semi-solid dosage CDMOs are becoming critical partners in ensuring product stability, bioavailability, and regulatory compliance. The rising demand for dermatological treatments, transdermal drug delivery systems, and topical pain relief products is further driving market growth. Additionally, advancements in controlled-release formulations and nanotechnology-based drug delivery are expanding the opportunities for semi-solid dosage CDMOs.What Innovations Are Transforming Semi-Solid Dosage CDMO Services?
Advancements in emulsification technology, microencapsulation, and liposomal drug delivery are enhancing the efficacy of semi-solid pharmaceutical formulations. AI-powered predictive modeling is being used to optimize formulation stability and manufacturing scalability. Additionally, the adoption of continuous manufacturing techniques is improving production efficiency, reducing costs, and minimizing batch variability. The rise of personalized medicine and targeted drug delivery systems is also leading to the development of patient-specific semi-solid formulations. These innovations are enabling CDMOs to offer more precise, high-quality pharmaceutical products.Which Therapeutic Areas Are Driving The Growth Of Semi-Solid Dosage CDMOs?
The dermatology sector is a major contributor to semi-solid dosage CDMO growth, with increasing demand for topical treatments for conditions such as psoriasis, eczema, and acne. The pain management and transdermal drug delivery segment is also expanding, as patients seek non-invasive alternatives to oral and injectable medications. The rise of hormone replacement therapy (HRT) and vaginal drug delivery systems is further contributing to market demand. Additionally, the wound care and burn treatment segment is driving innovation in semi-solid formulations with enhanced healing and antimicrobial properties.What Factors Are Fueling The Growth Of The Semi-Solid Dosage CDMO Market?
The growth of the semi-solid dosage CDMO market is being driven by increasing outsourcing trends in the pharmaceutical industry, rising demand for dermatological and transdermal treatments, and advancements in formulation science. Regulatory agencies are emphasizing quality control and Good Manufacturing Practices (GMP), further encouraging pharmaceutical companies to partner with specialized CDMOs. Additionally, the growth of emerging markets and the expansion of over-the-counter (OTC) semi-solid products are creating new opportunities for contract manufacturing. As pharmaceutical innovation continues, the role of semi-solid dosage CDMOs will become increasingly essential in drug development and production.Report Scope
The report analyzes the Semi-Solid Dosage CDMO market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Administration Route (Topical, Transdermal, Others); Product (Ointments, Creams & Lotions, Pastes, Gels, Others); Service (Contract Development, Contract Manufacturing); End-Use (Pharmaceutical Companies, Biopharmaceutical Companies, Others)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Topical segment, which is expected to reach US$36.5 Billion by 2030 with a CAGR of a 11.0%. The Transdermal segment is also set to grow at 9.0% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $9.1 Billion in 2024, and China, forecasted to grow at an impressive 14.3% CAGR to reach $12.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Semi-Solid Dosage CDMO Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Semi-Solid Dosage CDMO Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Semi-Solid Dosage CDMO Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Aenova Group, AGC Biologics, Alcami Corporation, Alchem Laboratories, Almac Group and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 32 Featured):
- Aenova Group
- AGC Biologics
- Alcami Corporation
- Alchem Laboratories
- Almac Group
- Ascendia Pharmaceuticals
- Avid Bioservices
- Boehringer Ingelheim
- Bora Pharmaceuticals
- Cambrex Corporation
- Catalent, Inc.
- Contract Pharmaceuticals Limited
- DPT Laboratories, Ltd.
- Fermion Oy
- Hetero Labs Limited
- Hovione
- Ind-Swift Laboratories Ltd.
- LGM Pharma
- Lonza Group
- Pace Analytical Life Sciences, LLC
- Patheon N.V.
- Pfizer CentreOne
- Pierre Fabre Group
- Piramal Pharma Solutions
- Recipharm AB
- Rubicon Research Pvt. Ltd.
- Sharp Services
- The Lubrizol Corporation
- TriRx Pharmaceutical Services
- WuXi AppTec
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What’s Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aenova Group
- AGC Biologics
- Alcami Corporation
- Alchem Laboratories
- Almac Group
- Ascendia Pharmaceuticals
- Avid Bioservices
- Boehringer Ingelheim
- Bora Pharmaceuticals
- Cambrex Corporation
- Catalent, Inc.
- Contract Pharmaceuticals Limited
- DPT Laboratories, Ltd.
- Fermion Oy
- Hetero Labs Limited
- Hovione
- Ind-Swift Laboratories Ltd.
- LGM Pharma
- Lonza Group
- Pace Analytical Life Sciences, LLC
- Patheon N.V.
- Pfizer CentreOne
- Pierre Fabre Group
- Piramal Pharma Solutions
- Recipharm AB
- Rubicon Research Pvt. Ltd.
- Sharp Services
- The Lubrizol Corporation
- TriRx Pharmaceutical Services
- WuXi AppTec
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 62 |
| Published | April 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 33.5 Billion |
| Forecasted Market Value ( USD | $ 60.8 Billion |
| Compound Annual Growth Rate | 10.5% |
| Regions Covered | Global |
